Clinical Trial Detail

NCT ID NCT02947347
Title Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Pharmacyclics LLC.
Indications

follicular lymphoma

Therapies

Ibrutinib

Ibrutinib + Rituximab

Age Groups: adult senior

No variant requirements are available.